FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2572796572> ?p ?o ?g. }

• W2572796572 endingPage "2420" @default.
• W2572796572 startingPage "2420" @default.
• W2572796572 abstract "Abstract Over-expression of anti-apoptotic members of the Bcl-2 family, including Bcl-2 and Bcl-XL, have been observed in more that 80% of B-cell Lymphomas. AT-101 has recently been found to be a potent small molecule inhibitor of Bcl-XL and Bcl-2. We investigated the toxicity and antitumor activity of oral AT-101 in SCID beige mice following subcutaneous injection with 1 x 107 RL-DLBCL cells. In the first experiment we explored four daily (25, 50, 75, 100 mg/kg) and three weekly (200, 240, 280 mg/kg) dose levels of AT-101 in cohorts of 5 mice. The 25 mg/kg/day for 4 weeks schedule exhibited the safest profile with some tumor growth delay compared to the control. Higher daily doses of 50, 75 and 100 mg/kg/day were associated with significant weight lost (i.e. > 10% of the initial weight) after 14, 10 and 7 days respectively, with death of all animals in these dose groups by day 23, 21 and 16 respectively. The weekly schedules exhibited later onset toxicity with the 240 mg/kg cohort exhibiting the best reduction in tumor growth compared to control (p=0.063). In a second single agent experiment additional schedules were explored to try to improve the toxicity profile. These schedules included 100, 120, 140 mg/kg on days 1, 4, 8, 11 followed by 1 week; a 35 and 50 mg/kg/day for 2 weeks out of 4; a 100 mg/kg for 3 days/week for 3 weeks out of 4; and a 240 and 280 mg/kg/week for 3 weeks out of 4. Significant weight loss was noted at 5–7 days in the dose groups at 100 mg/kg daily, 120–140 and 280 mg/kg. Overall, tumor volume assessment showed a statistically significant advantage for the 35 mg/kg daily schedule compared to control (p=0.008), with this dose and schedule being the most effective and least toxic. In terms of dose intensity, it's interesting to note that 35 mg/kg/day for two weeks delivered a total dose of 490 mg/kg. Combination experiments with cyclophosphamide (50 mg/kg) and rituximab (10 mg/mg) i.p. on days 2, 4, 6, 8 demonstrated marked improvement in favor of the triplet combination (see Fig. below). AT-101 (35 mg/kg) was administered p.o. from day 0 to day 9 These data suggest that targeting Bcl-2 and Bcl-XL with AT-101 may help chemosensitize lymphoma to conventional therapies and improve therapeutic outcomes. Download : Download high-res image (142KB) Download : Download full-size image" @default.
• W2572796572 created "2017-01-26" @default.
• W2572796572 creator A5000550102 @default.
• W2572796572 creator A5002126535 @default.
• W2572796572 creator A5008319308 @default.
• W2572796572 creator A5035087900 @default.
• W2572796572 creator A5051277222 @default.
• W2572796572 creator A5054745917 @default.
• W2572796572 creator A5062618199 @default.
• W2572796572 creator A5076577365 @default.
• W2572796572 date "2005-11-16" @default.
• W2572796572 modified "2023-09-29" @default.
• W2572796572 title "Targeting Antiapoptotic Bcl-2 Family Members with AT-101 in Pre-Clinical Models of Aggressive Lymphoma in Combination with Cyclophosphamide (C) and Rituximab (R) Produces a Marked Improvement in Therapeutic Efficacy." @default.
• W2572796572 doi "https://doi.org/10.1182/blood.v106.11.2420.2420" @default.
• W2572796572 hasPublicationYear "2005" @default.
• W2572796572 type Work @default.
• W2572796572 sameAs 2572796572 @default.
• W2572796572 citedByCount "1" @default.
• W2572796572 crossrefType "journal-article" @default.
• W2572796572 hasAuthorship W2572796572A5000550102 @default.
• W2572796572 hasAuthorship W2572796572A5002126535 @default.
• W2572796572 hasAuthorship W2572796572A5008319308 @default.
• W2572796572 hasAuthorship W2572796572A5035087900 @default.
• W2572796572 hasAuthorship W2572796572A5051277222 @default.
• W2572796572 hasAuthorship W2572796572A5054745917 @default.
• W2572796572 hasAuthorship W2572796572A5062618199 @default.
• W2572796572 hasAuthorship W2572796572A5076577365 @default.
• W2572796572 hasConcept C126322002 @default.
• W2572796572 hasConcept C2776694085 @default.
• W2572796572 hasConcept C2776755627 @default.
• W2572796572 hasConcept C2779338263 @default.
• W2572796572 hasConcept C2780653079 @default.
• W2572796572 hasConcept C29730261 @default.
• W2572796572 hasConcept C71924100 @default.
• W2572796572 hasConcept C72563966 @default.
• W2572796572 hasConcept C90924648 @default.
• W2572796572 hasConcept C98274493 @default.
• W2572796572 hasConceptScore W2572796572C126322002 @default.
• W2572796572 hasConceptScore W2572796572C2776694085 @default.
• W2572796572 hasConceptScore W2572796572C2776755627 @default.
• W2572796572 hasConceptScore W2572796572C2779338263 @default.
• W2572796572 hasConceptScore W2572796572C2780653079 @default.
• W2572796572 hasConceptScore W2572796572C29730261 @default.
• W2572796572 hasConceptScore W2572796572C71924100 @default.
• W2572796572 hasConceptScore W2572796572C72563966 @default.
• W2572796572 hasConceptScore W2572796572C90924648 @default.
• W2572796572 hasConceptScore W2572796572C98274493 @default.
• W2572796572 hasIssue "11" @default.
• W2572796572 hasLocation W25727965721 @default.
• W2572796572 hasOpenAccess W2572796572 @default.
• W2572796572 hasPrimaryLocation W25727965721 @default.
• W2572796572 hasRelatedWork W1443108546 @default.
• W2572796572 hasRelatedWork W1669741196 @default.
• W2572796572 hasRelatedWork W188284374 @default.
• W2572796572 hasRelatedWork W1968495511 @default.
• W2572796572 hasRelatedWork W1996198321 @default.
• W2572796572 hasRelatedWork W2040146091 @default.
• W2572796572 hasRelatedWork W2320930530 @default.
• W2572796572 hasRelatedWork W2323099604 @default.
• W2572796572 hasRelatedWork W2328602479 @default.
• W2572796572 hasRelatedWork W2366793750 @default.
• W2572796572 hasRelatedWork W2369764254 @default.
• W2572796572 hasRelatedWork W2373660558 @default.
• W2572796572 hasRelatedWork W2398845841 @default.
• W2572796572 hasRelatedWork W2410286296 @default.
• W2572796572 hasRelatedWork W2412227089 @default.
• W2572796572 hasRelatedWork W2460843389 @default.
• W2572796572 hasRelatedWork W2545657964 @default.
• W2572796572 hasRelatedWork W2978553166 @default.
• W2572796572 hasRelatedWork W3030508989 @default.
• W2572796572 hasRelatedWork W3096705707 @default.
• W2572796572 hasVolume "106" @default.
• W2572796572 isParatext "false" @default.
• W2572796572 isRetracted "false" @default.
• W2572796572 magId "2572796572" @default.
• W2572796572 workType "article" @default.